Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: Findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-3 trial

American Heart Journal

Volumn 155, Issue 2, 2008, Pages 388-394

  Pedrazzini, Giovanni ^a   Santoro, Eugenio ^b   Latini, Roberto ^b,e   Fromm, Laurie ^b   Franzosi, Maria Grazia ^b   Mocetti, Tiziano ^a   Staszewsky, Lidia ^b   Barlera, Simona ^b   Tognoni, Gianni ^c   Maggioni, Aldo P ^d  

^a DIVISION OF CARDIOLOGY   (Switzerland)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c Consorzio Mario Negri Sud ^*  (Italy)

^d ANMCO RESEARCH CENTER   (Italy)

^e NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; LISINOPRIL;

ACUTE HEART INFARCTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART ASSIST DEVICE; HEART DEATH; HEART RUPTURE; HUMAN; ITALY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SURVIVAL RATE; UNIVARIATE ANALYSIS;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HUMANS; LISINOPRIL; MALE; MYOCARDIAL INFARCTION; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 38349006586     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.10.015     Document Type: Article

References (34)

1. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J 6 (1985) 199-226
2. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 2 (1986) 57-66
3. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1 (1986) 397-402
4. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2 (1988) 349-360
5. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343 (1994) 311-322
6. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2). GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 336 (1990) 65-67
7. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 339 (1992) 753-770
8. Kleiman N.S., White H.D., Ohman E.M., et al. Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Circulation 90 (1994) 2568-2665
9. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI). GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343 (1994) 1115-1122
10. Swedberg K., Held P., Kjekshus J., et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 327 (1992) 678-684
11. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 345 (1995) 669-685
12. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction. Systematic overview of individual data from 100 000 patients in randomized trials. Circulation 97 (1998) 2202-2212
13. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn 6 weeks after acute myocardial infarction. The GISSI-3 trial. J Am Coll Cardiol 27 (1996) 337-344
14. Domanski M.J., Exner D.V., Borkowf C.B., et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. J Am Coll Cardiol 33 (1999) 598-604
15. Leri A., Claudio P.P., Li Q., et al. Stretch mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest 101 (1998) 1326-1342
16. Pfeffer M.A., and Hennekens C.H. When a question has an answer: rationale for our early termination of the HEART trial. Am J Cardiol 75 (1995) 1173-1175
17. Latini R., Maggioni A.P., Flather M., et al. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation 92 (1995) 3132-3137
18. Kleiman N.S., Terrin M., Mueller H., et al. Mechanisms of early death despite thrombolytic therapy: experience from the thrombolysis in myocardial infarction phase II (TIMI II) study. J Am Coll Cardiol 19 (1992) 1129-1135
19. Becker R.C., Charlesworth A., Wilcox R.G., et al. Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the Late Assessment of Thrombolytic Efficacy (LATE) Study. J Am Coll Cardiol 25 (1995) 1963-1968
20. Becker R.C., Gore J.M., Lambrew C., et al. A composite view of cardiac rupture in the United States national registry of myocardial infarction. J Am Coll Cardiol 27 (1996) 1321-1326
21. Zahger D., and Milgalter E. Clinical problem-solving. A broken heart. N Engl J Med 334 (1996) 319-321
22. Stevenson W.G., Linssen G.C., Havenith M.G., et al. The spectrum of death after myocardial infarction: a necropsy study. Am Heart J 118 (1989) 1182-1188
23. Coats A.J., and Adamopoulos S. Neurohormonal mechanisms and the role of angiotensin-converting enzyme (ACE) inhibitors in heart failure. Cardiovasc Drugs Ther 8 (1994) 685-692
24. St John Sutton M., Pfeffer M.A., Moye L., et al. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation 96 (1997) 3294-3299
25. Cody R.J., Covita A., Schaer G., et al. Captopril pharmacokinetics and the acute hemodynamic and hormonal response in patients with severe chronic congestive heart failure. Am Heart J 104 (1982) 1180-1183
26. St John Sutton M., Lee D., Rouleau J.L., et al. Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation 107 (2003) 2577-2582
27. Young J.B., Dunlap M.E., Pfeffer M.A., et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110 (2004) 2618-2626
28. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
29. Pitt B., Remme W., Zannad F., et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
30. Maggioni A.P., Maseri A., Fresco C., et al. Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. The Investigators of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2). N Engl J Med 329 (1993) 1442-1448
31. Malacrida R., Genoni M., Maggioni A.P., et al. A comparison of the early outcome of acute myocardial infarction in women and men. The Third International Study of Infarct Survival Collaborative Group. N Engl J Med 338 (1998) 8-14
32. Volpi A., De Vita C., Franzosi M.G., et al. Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis. Results of the GISSI-2 data base. The Ad hoc Working Group of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-2 Data Base. Circulation 88 (1993) 416-429
33. Weaver W.D., White H.D., Wilcox R.G., et al. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. JAMA 275 (1996) 777-782
34. Zuanetti G., Latini R., Maggioni A.P., et al. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol 22 (1993) 1788-1794